Literature DB >> 4629776

Investigation of cross-link formation in DNA by the alkylating cytostatic IMET 3106, 3393 and 3943.

M Hartmann, C Zimmer.   

Abstract

Mesh:

Substances:

Year:  1972        PMID: 4629776     DOI: 10.1016/0005-2787(72)90282-1

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


× No keyword cloud information.
  14 in total

1.  Bendamustine in B-Cell Malignancies: The New 46-Year-Old Kid on the Block.

Authors:  Varsha Gandhi; Jan A Burger
Journal:  Clin Cancer Res       Date:  2009-12-15       Impact factor: 12.531

2.  Conformational changes of nucleic acids and poly (d(A-T)-d(A-T)) caused by photoaddition of furocoumarins.

Authors:  L Kittler; C Zimmer
Journal:  Nucleic Acids Res       Date:  1976-01       Impact factor: 16.971

Review 3.  Bendamustine and its role in the treatment of unfit patients with chronic lymphocytic leukaemia: a perspective review.

Authors:  Othman Al-Sawaf; Paula Cramer; Valentin Goede; Michael Hallek; Natali Pflug
Journal:  Ther Adv Hematol       Date:  2017-03-30

4.  Bendamustine in the treatment of non-Hodgkin's lymphomas.

Authors:  Fredrick Hagemeister; George Manoukian
Journal:  Onco Targets Ther       Date:  2009-02-18       Impact factor: 4.147

5.  Post-transplant bendamustine reduces GvHD while preserving GvL in experimental haploidentical bone marrow transplantation.

Authors:  Jessica Stokes; Emely A Hoffman; Yi Zeng; Nicolas Larmonier; Emmanuel Katsanis
Journal:  Br J Haematol       Date:  2016-03-31       Impact factor: 6.998

Review 6.  Imidazoles as potential anticancer agents.

Authors:  Imran Ali; Mohammad Nadeem Lone; Haasan Y Aboul-Enein
Journal:  Medchemcomm       Date:  2017-04-13       Impact factor: 3.597

7.  The role of bendamustine in the treatment of indolent non-Hodgkin lymphoma.

Authors:  Ibrahim T Aldoss; Susan M Blumel; Philip J Bierman
Journal:  Cancer Manag Res       Date:  2009-11-12       Impact factor: 3.989

8.  Bendamustine: safety and efficacy in the management of indolent non-hodgkins lymphoma.

Authors:  Nishant Tageja
Journal:  Clin Med Insights Oncol       Date:  2011-05-18

Review 9.  Chemotherapy induced DNA damage response: convergence of drugs and pathways.

Authors:  Derek Woods; John J Turchi
Journal:  Cancer Biol Ther       Date:  2013-02-04       Impact factor: 4.742

10.  Bendamustine HCL for the treatment of relapsed indolent non-Hodgkin's lymphoma.

Authors:  Rudolf Weide
Journal:  Ther Clin Risk Manag       Date:  2008-08       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.